GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

SAN FRANCISCO -- Menopause hormone therapy (MHT) was tied to a weight-loss boost in postmenopausal women taking a weight loss ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Healio and Endocrine Today editors have compiled the top obesity news from 2022. Readers were most interested in the latest trial data on anti-obesity medications, such as semaglutide (Wegovy ...

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.